Logo do repositório
 
Publicação

MetE: a promising protective antigen for tuberculosis vaccine development

2025-07-21Artigo de investigação Acesso aberto
Ver registo simples
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorAlmujri, Salem Salman
dc.contributor.authorStylianou, Elena
dc.contributor.authorNicastri, Annalisa
dc.contributor.authorSatti, Iman
dc.contributor.authorKorompis, Marcellus
dc.contributor.authorLi, Shuailin
dc.contributor.authorVoss, Christopher J. De
dc.contributor.authorAlvarez, Marco Polo Peralta
dc.contributor.authorTanner, Rachel
dc.contributor.authorBettencourt, Paulo J. G.
dc.contributor.authorTernette, Nicola
dc.contributor.authorMcShane, Helen
dc.date.accessioned2025-09-05T08:36:03Z
dc.date.available2025-09-05T08:36:03Z
dc.date.issued2025-07-21
dc.description.abstractIntroduction: Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), remains a significant global health concern. The existing vaccine, Bacillus Calmette-Guérin (BCG), provides inconsistent protection, highlighting the pressing need for a more effective vaccine. We aimed to identify novel MTB antigens and assess their protective efficacy as TB vaccine candidates. Methods: Using immunopeptidomics, we identified 64 and 80 unique mycobacterial antigens derived from BCG and MTB, respectively. We prioritised antigens based on HLA allele coverage through an immunoinformatics approach. Results: The candidates, hisD, metE, and mmpL12, delivered as DNA vaccines, were evaluated for efficacy in mice using the ex vivo Mycobacterial Growth Inhibition Assay (MGIA) and metE was identified as a promising candidate. In vivo murine MTB challenge experiments confirmed the protective efficacy conferred by metE when formulated as recombinant protein with AS01™ or AddaS03™ adjuvants, compared to the naïve group. The immunogenic profiles of metE formulated in the two different adjuvants differed, with metE-AS01™ inducing antigen-specific IFN-?, TNF-?, IL-2, IL-17, IgG1 and IgG2a-c, while metE-AddaS03™ induced TNF-?, IL-2, IL-17, IL-4, IgM, IgG1, IgG2b. Conclusion: Our findings highlight metE as a promising protective antigen for future TB vaccine development.eng
dc.identifier.citationAlmujri, S. S., Stylianou, E., Nicastri, A., & Satti, I. et al. (2025). MetE: a promising protective antigen for tuberculosis vaccine development. Frontiers in Immunology, 16, Article 1593263. https://doi.org/10.3389/fimmu.2025.1593263
dc.identifier.doi10.3389/fimmu.2025.1593263
dc.identifier.eid105012460584
dc.identifier.issn1664-3224
dc.identifier.other2524d86c-d02f-4404-96b5-32c2259e55f6
dc.identifier.pmcPMC12319054
dc.identifier.pmid40761798
dc.identifier.urihttp://hdl.handle.net/10400.14/54680
dc.identifier.wos001542659100001
dc.language.isoeng
dc.peerreviewedyes
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAntigen discovery
dc.subjectHLA/MHC
dc.subjectImmunoinformatics
dc.subjectImmunopeptidomics
dc.subjectMass spectrometry
dc.subjectMycobacterium tuberculosis
dc.subjectTuberculosis
dc.subjectVaccines
dc.titleMetE: a promising protective antigen for tuberculosis vaccine developmenteng
dc.typeresearch article
dspace.entity.typePublication
oaire.citation.titleFrontiers in Immunology
oaire.citation.volume16
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
126284609.pdf
Tamanho:
3.19 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

CIIS - Contribuições em Revistas Científicas / Contribution to Journals